- Home
- SPRO vs RMTI Comparison
SPRO vs RMTI Comparison
Compare SPRO & RMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- RMTI
- Stock Information
- Founded
- SPRO 2013
- RMTI 1994
- Country
- SPRO United States
- RMTI United States
- Employees
- SPRO N/A
- RMTI N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- RMTI Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- RMTI Health Care
- Exchange
- SPRO Nasdaq
- RMTI Nasdaq
- Market Cap
- SPRO 40.5M
- RMTI 34.9M
- IPO Year
- SPRO 2017
- RMTI 1998
- Fundamental
- Price
- SPRO $0.62
- RMTI $1.12
- Analyst Decision
- SPRO Buy
- RMTI Strong Buy
- Analyst Count
- SPRO 4
- RMTI 2
- Target Price
- SPRO $5.00
- RMTI $4.00
- AVG Volume (30 Days)
- SPRO 113.5K
- RMTI 182.2K
- Earning Date
- SPRO 05-13-2025
- RMTI 05-12-2025
- Dividend Yield
- SPRO N/A
- RMTI N/A
- EPS Growth
- SPRO N/A
- RMTI N/A
- EPS
- SPRO N/A
- RMTI N/A
- Revenue
- SPRO $47,977,000.00
- RMTI $101,489,000.00
- Revenue This Year
- SPRO N/A
- RMTI N/A
- Revenue Next Year
- SPRO N/A
- RMTI $10.42
- P/E Ratio
- SPRO N/A
- RMTI N/A
- Revenue Growth
- SPRO N/A
- RMTI 21.38
- 52 Week Low
- SPRO $0.51
- RMTI $0.86
- 52 Week High
- SPRO $1.72
- RMTI $5.15
- Technical
- Relative Strength Index (RSI)
- SPRO 41.34
- RMTI 46.38
- Support Level
- SPRO $0.64
- RMTI $1.08
- Resistance Level
- SPRO $0.75
- RMTI $1.21
- Average True Range (ATR)
- SPRO 0.05
- RMTI 0.08
- MACD
- SPRO -0.01
- RMTI 0.02
- Stochastic Oscillator
- SPRO 21.63
- RMTI 36.67
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.